Financial Performance Overview
Mankind Pharma Limited reported strong financial results for FY 2025-26 with consolidated revenue of ₹14,277.64 crores, representing 17% year-over-year growth. The company achieved an adjusted EBITDA margin of 25.4% with standalone net profit of ₹2,037.56 crores and consolidated net profit of ₹1,912.93 crores. Operating cash flow was robust at ₹3,121.29 crores, while the company maintained cash equivalents of ₹391.69 crores as of March 31, 2026.
Capital Structure and Borrowings
The company's equity capital increased to ₹41.28 crores through employee stock option exercises, while promoter holding remained stable at 72.65%. Total borrowings stood at ₹6,204.34 crores, including secured Non-Convertible Debentures of ₹4,970.56 crores which are secured by pledge of shares of Bharat Serums and Vaccines Limited. The gearing ratio improved to 25.06% from 33.40% in FY25.
Annual General Meeting and Corporate Governance
Mankind Pharma issued notice for its 35th Annual General Meeting scheduled for August 4, 2026, to be held virtually through VC/OAVM. The agenda includes reappointment of directors Rajeev Juneja and Satish Kumar Sharma, and ratification of cost auditor remuneration. Remote e-voting will be available from August 1-3, 2026, with CDSL serving as the e-voting agency.
Business Responsibility and Sustainability Report
The company published its standalone Business Responsibility and Sustainability Report for FY25-26, disclosing a turnover of ₹10,421.18 crores and net worth of ₹16,396.94 crores. The report outlines material ESG risks including climate change, water management, and regulatory compliance, with key sustainability targets including achieving carbon neutrality by FY 2030 and 100% renewable power by FY 2030. Current progress shows 72.14% reduction in emissions from base year.
Related Party Transactions and Subsidiaries
Significant related party transactions totaled ₹373.21 crores in goods purchases with subsidiaries and ₹338.58 crores in loans. The company maintains 47 subsidiaries and 6 associates, with the acquisition of Bharat Serums and Vaccines Limited for ₹13,834.58 crores resulting in ₹6,472.61 crores of goodwill recognition. Employee Stock Option Plan 2022 had 855,430 options outstanding at weighted average exercise price of ₹946.51.
Exceptional Items and Tax Matters
Exceptional items of ₹106.24 crores were recognized, primarily due to Labour Code implementation impact and stamp duty on IP acquisition. The company faces income tax disputes amounting to ₹898.32 crores pending with Commissioner of Income Tax (Appeals), with ₹227.58 crores paid under protest.
Regulatory Compliance and Disclosures
All disclosures were made in accordance with SEBI Listing Regulations and Companies Act, 2013 requirements. The company maintained compliance with environmental regulations across all manufacturing sites and obtained independent assurance from SGS India for BRSR disclosures. The financial statements were prepared following Indian Accounting Standards (Ind-AS) and received audit approval from S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co.